This cost-utility analysis compares the cost-effectiveness of salmeterol, fluticasone propionate, combination salmeterolfluticasone, and no maintenance therapy in chronic obstructive pulmonary disease.
Yuji Oba, MD
Advertisement
Articles by Yuji Oba, MD
Continuous home oxygen therapy for chronic obstructive pulmonary disease seems more cost-effective than other health technologies covered by Medicare, while nocturnal oxygen therapy is not.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
4
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
5